Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AURORA: Flurpiridaz PET MPI for Suspected CAD
NCT03354273Phase 3Completed
- Sponsor
- GE HealthCare
- Start
- Jun 2018
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of Flurpiridaz F 18 in coronary artery disease (CAD), sponsored by GE HealthCare. Started Jun 2018; status: completed.
02
Drugs
Flurpiridaz F 18
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03354273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03354273.